Latest News

NABP’s new uniform pharmacy law exam streamlines multistate licensure, reshapes MPJE prep, and speeds pharmacist mobility in 2026.

At AXS2026, pharmacy and health care leaders explored how AI is transforming specialty care and why standards, trust, and oversight must keep pace with innovation.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

The rare disease space is an area where scientific rigor meets genuine human impact.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

Pharmacists drive acne management by choosing proven OTC ingredients, coaching skin care routines, debunking trends, and knowing when to refer patients to specialists.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly intravenous infusions, supported by robust phase 3 data.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

Sports Pharmacy Summit unites global experts on anti-doping, supplement safety, and data-driven performance to protect athlete health.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.

The treatment's approval was supported by positive evidence from the phase 1/2 CHORD clinical trial.

Emerging data found that initiating low-dose aspirin at giant cell arteritis diagnosis was associated with reduced 1-year major cardiovascular events but an increased risk of major bleeding.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-fighting immune cells.

New Yale University research offers reassurance for pregnant patients and their clinicians, although evidence of lasting structural damage remains a concern.